Microbial biopharmaceuticals Market: By Microbe Type, By End product, By Application and Region Forecast 2021-2032

Microbial biopharmaceuticals Market Size, Share, Growth, Trends, and Global Industry Analysis: By Microbe Type (Bacteria, Fungal & Yeast, Virus), By End product (Vaccines, Hormones, Antibody Derived Proteins, PEGylated Products, BL-2 Products), By Application (Metabolic Disorders, Hormonal Disorders, Homological Disorders, Oncological Disorders) and Region Forecast 2021-2032

Report ID:40305

Published Date:Sep 2025

No of Pages:228

Format:

Microbial Biopharmaceuticals Market size was valued at US$ 405.2 billion in 2025 and is expected to reach US$ 1,058.4 billion by 2032, growing at a significant CAGR of 14.7% from 2026-2032. The market Increase in the geriatric population and changes in lifestyles are increasing the demand for biopharmaceuticals. An increase in research facilities and more approved biopharmaceutical products in the market are also key factors affecting the market. Frequent cases of side effects and incompatibilities in cases of mammalian or plant-obtained biopharmaceutical products cause the rise in demand for microbial products as they do not possess any side effects. They can be manufactured easily at low cost and are more stable in atmospheric and biological conditions.

Microbes have been used to make bread, wine, vinegar, and other common items for millennia, with no one knowing the scientific basis. Nonmicrobial goods such as insulin, interferon, human growth hormone, and viral vaccinations are now commercially produced using genetically altered organisms. Microbes are also employed to produce energy (biodiesel and bioethanol), as well as to clean up contaminants like sewage and oil spills. Microorganisms contribute to increased agricultural production as active ingredients in biofertilizers and biopesticides, and microbes are the foundation of cost-effective mining and metallurgical technologies. The global market is surging owing to frequent acquisitions and launches by the market players.

Key Development:

  • In 2013, Sanofi a French pharmaceutical company announced that a strain of baker's yeast capable of producing malaria drugs on an industrial scale had been successfully engineered by their researchers and it is commercially available now.

Microbial Biopharmaceuticals Market Summary

Study Period

2026-2032

Base Year

2025

CAGR

14.7%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Microbial Biopharmaceuticals Market Dynamics

Microbial biopharmaceuticals are simply defined as biopharmaceutical products which are extracted from microbial species by using recombinant DNA technology. These products have various benefits when compared to other biopharmaceutical products such as easy manufacture and extraction, low of cost, more stability, high potency, no or very less side effects and high therapeutic nature etc. thus, the market for these microbial biopharmaceuticals are showing significant growth.

Microbial Biopharmaceuticals Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2026-2032

Market CAGR

14.7%

By Microbe Type

  • Bacteria
  • Fungal & Yeast
  • Virus
  • Other microbes

By End Product

  • Vaccines
  • Hormones
  • Antibody derived proteins
  • PEGylated products
  • BL-2 Products

By Application

  • Metabolic disorders
  • Hormonal disorders
  • Hematological disorders
  • Oncological disorders
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The microbial biopharmaceuticals market report provides granular level information about the market size, regional market share, historic market (2021-2025), and forecast (2026-2032)
  • The report covers in-detail insights into the competitor's overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

Microbial Biopharmaceuticals Market size was valued at US$ 405.2 billion in 2025 and is expected to reach US$ 1,058.4 billion by 2032, growing at a significant CAGR of 14.7% from 2026-2032

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The market key players are AbbVie Inc. (Abbott), A-Bio Pharma Pte Ltd., ABL, Inc., Affinity Life Sciences, Inc., Ajinomoto Aminoscience, LLC, Alexion Pharmaceuticals, Alliance Medical Products, Inc.

Content Updated Date: Feb 2026

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Microbial Biopharmaceuticals Market Introduction 
2.1.Global Microbial Biopharmaceuticals Market  - Taxonomy
2.2.Global Microbial Biopharmaceuticals Market  - Definitions
2.2.1.Microbe Type
2.2.2.End Product
2.2.3.Application
2.2.4.Region
3.Global Microbial Biopharmaceuticals Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Microbial Biopharmaceuticals Market Analysis, 2021 - 2025 and Forecast 2026- 2032
4.1.  Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Microbial Biopharmaceuticals Market  By Microbe Type, 2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
5.1. Bacteria
5.1.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Fungal & Yeast
5.2.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Virus
5.3.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Other microbes
5.4.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Microbial Biopharmaceuticals Market  By End Product, 2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
6.1. Vaccines
6.1.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Hormones
6.2.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Antibody derived proteins
6.3.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. PEGylated products
6.4.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. BL-2 Products
6.5.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Microbial Biopharmaceuticals Market  By Application, 2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
7.1. Metabolic disorders
7.1.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Hormonal disorders
7.2.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Hematological disorders
7.3.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Oncological disorders
7.4.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Others
7.5.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.Global Microbial Biopharmaceuticals Market  By Region, 2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2021 - 2025 and Forecast, 2026- 2032, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Microbial Biopharmaceuticals Market ,2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
9.1. Microbe Type Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Bacteria
9.1.2.Fungal & Yeast
9.1.3.Virus
9.1.4.Other microbes
9.2.  End Product Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Vaccines
9.2.2.Hormones
9.2.3.Antibody derived proteins
9.2.4.PEGylated products
9.2.5.BL-2 Products
9.3.  Application Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Metabolic disorders
9.3.2.Hormonal disorders
9.3.3.Hematological disorders
9.3.4.Oncological disorders
9.3.5.Others
9.4.  Country Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Microbial Biopharmaceuticals Market ,2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
10.1. Microbe Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Bacteria
10.1.2.Fungal & Yeast
10.1.3.Virus
10.1.4.Other microbes
10.2.  End Product Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Vaccines
10.2.2.Hormones
10.2.3.Antibody derived proteins
10.2.4.PEGylated products
10.2.5.BL-2 Products
10.3.  Application Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Metabolic disorders
10.3.2.Hormonal disorders
10.3.3.Hematological disorders
10.3.4.Oncological disorders
10.3.5.Others
10.4.  Country Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Microbial Biopharmaceuticals Market ,2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
11.1. Microbe Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Bacteria
11.1.2.Fungal & Yeast
11.1.3.Virus
11.1.4.Other microbes
11.2.  End Product Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Vaccines
11.2.2.Hormones
11.2.3.Antibody derived proteins
11.2.4.PEGylated products
11.2.5.BL-2 Products
11.3.  Application Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Metabolic disorders
11.3.2.Hormonal disorders
11.3.3.Hematological disorders
11.3.4.Oncological disorders
11.3.5.Others
11.4.  Country Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Microbial Biopharmaceuticals Market ,2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
12.1. Microbe Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Bacteria
12.1.2.Fungal & Yeast
12.1.3.Virus
12.1.4.Other microbes
12.2.  End Product Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Vaccines
12.2.2.Hormones
12.2.3.Antibody derived proteins
12.2.4.PEGylated products
12.2.5.BL-2 Products
12.3.  Application Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Metabolic disorders
12.3.2.Hormonal disorders
12.3.3.Hematological disorders
12.3.4.Oncological disorders
12.3.5.Others
12.4.  Country Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Microbial Biopharmaceuticals Market ,2021 - 2025 and Forecast 2026- 2032 (Sales Value USD Million)
13.1. Microbe Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Bacteria
13.1.2.Fungal & Yeast
13.1.3.Virus
13.1.4.Other microbes
13.2.  End Product Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Vaccines
13.2.2.Hormones
13.2.3.Antibody derived proteins
13.2.4.PEGylated products
13.2.5.BL-2 Products
13.3.  Application Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Metabolic disorders
13.3.2.Hormonal disorders
13.3.3.Hematological disorders
13.3.4.Oncological disorders
13.3.5.Others
13.4.  Country Analysis 2021 - 2025 and Forecast 2026- 2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.AbbVie Inc. (Abbott)
14.2.2.A-Bio Pharma Pte Ltd.
14.2.3.ABL, Inc.
14.2.4.Affinity Life Sciences, Inc.
14.2.5.Ajinomoto Aminoscience, LLC
14.2.6.Alexion Pharmaceuticals
14.2.7.Alliance Medical Products, Inc.
14.2.8.Alpha Biologics
14.2.9.Baxter BioPharma Solutions/Baxter Bioscience
14.2.10.Biogen Idec
14.2.11.BIOMEVA GmbH
14.2.12.Biotecnol
14.2.13.Boehringer Ingelheim GmbH
14.2.14.Boston Mountain Biotech
14.2.15.Celonic
14.2.16.Crucell /Johnson & Johnson
14.2.17.FUJIFILM Diosynth Biotechnologies
14.2.18.Genentech/Roche
14.2.19.GlaxoSmithKline
14.2.20.Glycobia
14.2.21.Lonza AG
14.2.22.Merck & Co. Inc
14.2.23.Novartis
14.2.24.Pfizer
14.2.25.ProBioGen AG
14.2.26.Regeneron Pharmaceuticals
14.2.27.Rentschler Biotechnologie
14.2.28.Royal DSM
14.2.29.Sandoz
14.2.30.Sanofi Pasteur
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • AbbVie Inc. (Abbott)
  • A-Bio Pharma Pte Ltd.
  • ABL, Inc.
  • Affinity Life Sciences, Inc.
  • Ajinomoto Aminoscience, LLC
  • Alexion Pharmaceuticals
  • Alliance Medical Products, Inc.
  • Alpha Biologics
  • Baxter BioPharma Solutions/Baxter Bioscience
  • Biogen Idec
  • BIOMEVA GmbH
  • Biotecnol
  • Boehringer Ingelheim GmbH
  • Boston Mountain Biotech
  • Celonic
  • Crucell /Johnson & Johnson
  • FUJIFILM Diosynth Biotechnologies
  • Genentech/Roche
  • GlaxoSmithKline
  • Glycobia
  • Lonza AG
  • Merck & Co. Inc
  • Novartis
  • Pfizer
  • ProBioGen AG
  • Regeneron Pharmaceuticals
  • Rentschler Biotechnologie
  • Royal DSM
  • Sandoz
  • Sanofi Pasteur

Related Industry Reports